Holen Sie sich die Stockscreener-App
24.29
2.71%
0.64
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Beam Therapeutics SVP Bethany Cavanagh Sells 187 Shares to Cover RSU Tax Withholding - Kalkine Media
To cover taxes, Beam Therapeutics (BEAM) treasurer sells 187 shares automatically. - Stock Titan
Beam Therapeutics Inc (NASDAQ: BEAM) Share Price, BEAM Stock News, BEAM Share Price & Updates - kalkine.ca
Beam Therapeutics (BEAM) president gifts shares to a family trust and retains 130,504 directly. - Stock Titan
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Clinical Trial Progress Might Change The Case For Investing In Beam Therapeutics Stock (BEAM) - webull.com
Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View - Seeking Alpha
Beam Therapeutics faces securities fraud probe after clinical trial safety concerns cause stock to drop 9.5%. - Pluang
Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit? - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc.BEAM - PR Newswire
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin DeficiencySlideshow (NASDAQ:BEAM) 2026-09-10 - Seeking Alpha
Beam Therapeutics Inc. (BEAM) Presents at European Respiratory Society (ERS) CongressSlideshow - Seeking Alpha
Beam Therapeutics at cantor conference: base editing lead comes into focus - Investing.com Canada
Cathie Wood’s ARK sells Alphabet stock, buys Meta and Beam Therapeutics - Investing.com
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com India
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com Canada
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com UK
Transcript : Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01 - marketscreener.com
Why (BEAM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $80 - Moomoo
BEAM Reiterated by Wedbush -- Price Target Maintained at $65 - GuruFocus
Beam Therapeutics (NasdaqGS:BEAM) Stock Forecast & Analyst Predictions - Simply Wall Street
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $43 - Moomoo
BEAM Looks 14.6% Overvalued on GF Value™ - GuruFocus
Beam Therapeutics at Wells Fargo conference: base editing gains ground By Investing.com - Investing.com India
Beam Therapeutics at Wells Fargo conference: base editing gains ground By Investing.com - Investing.com UK
Beam drops after updating Phase 1/2 trial data for gene-editing drug - Seeking Alpha
3 Promising Genomics Stocks in the Spotlight in 2026 - TradingView
BEAM - Finviz
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment - Yahoo Finance
Beam Therapeutics reports BEAM-302 AATD trial update - grafa.com
BEAM Looks 26.9% Overvalued on GF Value™ - GuruFocus
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 - manilatimes.net
Beam Therapeutics Presents Updated Clinical Data from the - GlobeNewswire
Beam Therapeutics (BEAM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
BEAM Should I Buy - Intellectia AI
Beam Therapeutics appoints Eric Foster as CCO - The Pharma Letter
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com Nigeria
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com South Africa
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com Canada
Beam Therapeutics names Eric Foster as chief commercial officer - Investing.com
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer - Barchart.com
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer - Stock Titan
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences - news.futunn.com
Three Beam Therapeutics talks will be webcast from Boston and New York - Stock Titan
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences - GlobeNewswire
Beam Therapeutics (BEAM) Stock May Look Stretched As Sales Expectations Climb - Yahoo Finance
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains - TradingView
5.00%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):